We are delighted to announce that Eagle IP has been recognized once more as a Highly Recommended Firm in Patent Prosecution by IAM Patent 1000 for 2025. IAM has highlighted Eagle IP as a “compact yet preeminent ensemble” that is adept at “working as a team on global patent matters” and “effective handling of multi-jurisdictional strategies.”

IAM has further highlighted five individuals from our firm:  Our President and Managing Director, Ms. Jennifer Che as a Highly Recommended Individual, Principal Ms. Yolanda Wang as a Recommended Individual, Principal Ms. Pauli Wong as a Next Generation, and Dr. Jacqueline C Lui and Dr. Ho Chung Lui as Luminaries.

It is with great pride that we have been included in this highest category among just a select few of Hong Kong’s top IP firms. We are deeply grateful to IAM for this recognition of our work. At Eagle IP, we are dedicated to providing exceptional service to our clients by drawing upon our hands-on knowledge of US and Chinese patent law, our proven ability to craft sophisticated and creative patent strategies, and our strong technical expertise. We will continue to build upon these strengths to deliver the highest level of service and support to the innovators who entrust us with protecting their groundbreaking ideas.

As always, a huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

我們過去活動

Recommended Insights

Stay Ahead: Getting a Chinese Patent in Three Months?

2024年4月23日
The China National Intellectual Property Administration (CNIPA) has announced a significant development in the realm of patent prosecution: the initiation of the "PPH Improvement Initiative" in collaboration with key patent offices from the United States, Europe, Japan, and South Korea. This initiative aims to elevate the user experience of the Patent Prosecution Highway (PPH) by […]

Do Invention and UM Patents Filed on the Same Day Rise and Fall Together?

2021年8月19日
Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape Seminal Cases by the SPC Recently, the Intellectual Property Division of the Supreme People's Court (SPC) issued a list of seminal (精品) cases. Although China is not a case law country, such seminal cases issued by the SPC have high guiding impact for […]

China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux

2021年5月24日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

Compositions Limited by Use: A Cautionary Tale

2022年10月26日
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]
Top crossarrow-right